Did you know that your use of the social media in certain ways can be violative of the sweeping and highly generalized definition that the FDA has of labeling? This definition is so broad in its reach that it considers what is said or represented, even by images, in a social media platform, as labeling, whose violation can attract penalties!
The FDA is very finicky about what is broadcast on the social media because information pertaining to it can be false. If false information reaches a consumer, it opens up the path to many unnecessary consequences and complex actions. The FDA is worried about potentially false information about it that could reach people through the social media, even if the consumer is not the one who has published it.
A big challenge for such companies is how to monitor and counter what someone else is saying about their product in a public forum. They need to be aware of the scope of their responsibility when such off-label information goes out into the open.
In-depth and accurate knowledge of delicate aspects such as this will be imparted at a webinar that Compliance4All, a leading provider of professional training for all the areas of regulatory compliance, is organizing on September 23.
Casper Uldriks, who owns the firm, Encore Insight LLC, will be the speaker at this meaningful and valuable session. Please enroll for it be visiting https://www.compliance4all.com/control/w_product/~product_id=502654LIVE
The main focus areas of this very interactive webinar include what is considered “off-label”, using social media website “likes” and links, the many pitfalls associated with Direct to Consumer promotion, and how to disseminate and absorb what the FDA considers fair and balanced information.
At this sixty-minute session, Casper will cover the following areas:
- Understand how social media is labeling
- Learn how third parties place you in jeopardy
- Understand FDA’s concern about “fair and balanced” information
- Ways to define your social media responsibilities
- Apply FDA Guidance Documents on DTC/social media labelling.
About the speaker:
Casper Uldriks, who owns the firm, Encore Insight LLC, specialized in the FDA’s medical device program as a field investigator, and served as a senior manager in the Office of Compliance and an Associate Center Director for the Center for Devices and Radiological Health. He developed enforcement actions and participated in the implementation of new statutory requirements.
To continue this interesting Post to read https://t2m.io/qfZYqmtE